These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2422 related items for PubMed ID: 15191204

  • 21. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 22. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease.
    Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, D'Armiento F, Romeo EF, Cucchiara S.
    Dig Liver Dis; 2006 Jun 10; 38(6):381-7. PubMed ID: 16301010
    [Abstract] [Full Text] [Related]

  • 23. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
    Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB.
    Gastrointest Endosc; 2006 Mar 10; 63(3):433-42; quiz 464. PubMed ID: 16500392
    [Abstract] [Full Text] [Related]

  • 24. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):851-8. PubMed ID: 16918890
    [Abstract] [Full Text] [Related]

  • 25. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
    Persoons P, Vermeire S, Demyttenaere K, Fischler B, Vandenberghe J, Van Oudenhove L, Pierik M, Hlavaty T, Van Assche G, Noman M, Rutgeerts P.
    Aliment Pharmacol Ther; 2005 Jul 15; 22(2):101-10. PubMed ID: 16011668
    [Abstract] [Full Text] [Related]

  • 26. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
    Eivindson M, Grønbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF.
    Scand J Gastroenterol; 2007 Apr 15; 42(4):464-70. PubMed ID: 17454856
    [Abstract] [Full Text] [Related]

  • 27. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ, International Organization for the Study of Inflammatory Bowel Diseases.
    Gastroenterology; 2013 Nov 15; 145(5):978-986.e5. PubMed ID: 23954314
    [Abstract] [Full Text] [Related]

  • 28. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
    Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, Emmons J, Martinez A, Kelly KJ, Binion DG.
    Am J Gastroenterol; 2002 Jun 15; 97(6):1408-14. PubMed ID: 12094858
    [Abstract] [Full Text] [Related]

  • 29. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
    Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG.
    Eur J Gastroenterol Hepatol; 2009 Sep 15; 21(9):1042-8. PubMed ID: 20139856
    [Abstract] [Full Text] [Related]

  • 30. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
    Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M, Italian Multicentric Study Group on Infliximab.
    Dig Liver Dis; 2005 Aug 15; 37(8):577-83. PubMed ID: 15886081
    [Abstract] [Full Text] [Related]

  • 31. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
    Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S.
    Aliment Pharmacol Ther; 2005 Oct 01; 22(7):613-26. PubMed ID: 16181301
    [Abstract] [Full Text] [Related]

  • 32. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF, Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
    Gastroenterology; 2006 Apr 01; 130(4):1054-61. PubMed ID: 16618399
    [Abstract] [Full Text] [Related]

  • 33. Infliximab treatment and prognostic factors for response in patients with Crohn's disease.
    Mendoza JL, García-Paredes J, Cruz Santamaria DM, Lana R, Ramírez Fernández E, Rodríguez Asteaga E, Díaz-Rubio M.
    Rev Esp Enferm Dig; 2002 May 01; 94(5):269-79. PubMed ID: 12474335
    [Abstract] [Full Text] [Related]

  • 34. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May 01; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

  • 35. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP.
    Dis Colon Rectum; 2007 Nov 01; 50(11):1754-60. PubMed ID: 17899271
    [Abstract] [Full Text] [Related]

  • 36. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec 01; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 37. Infliximab: new preparation. A last resort for Crohn's disease.
    Prescrire Int; 2000 Dec 01; 9(50):163-5. PubMed ID: 11475490
    [Abstract] [Full Text] [Related]

  • 38. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684
    [Abstract] [Full Text] [Related]

  • 39. Infliximab treatment for symptomatic Crohn's disease strictures.
    Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC.
    Aliment Pharmacol Ther; 2009 Feb 01; 29(3):279-85. PubMed ID: 19035967
    [Abstract] [Full Text] [Related]

  • 40. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ.
    Eur J Gastroenterol Hepatol; 2009 Jan 01; 21(1):71-5. PubMed ID: 19060632
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 122.